Lantern Pharma Inc.: Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas
Lantern Pharma (LTRN) received a USPTO Notice of Allowance for LP-284, extending patent protection to 2042 for treating mantle cell lymphoma and double-hit lymphoma. The patent covers LP-284 as a monotherapy and in combination with other anti-cancer agents. LP-284 is in a Phase 1 clinical trial and has three FDA Orphan Drug Designations.
How this was made
The 30-second read
Why it matters
The new method‑of‑use patent adds a layer of protection beyond the existing composition‑of‑matter estate, extending exclusivity to 2042 and may improve the company's long‑term valuation outlook.
Market read
The patent allowance is a material corporate development for LTRN, offering extended market exclusivity and potentially supporting future financing or partnership discussions.
What to watch
Potential challenges in regulatory approval and competition from other acylfulvene candidates could offset the IP benefit.
Background
Lantern Pharma (NASDAQ:LTRN) is an AI‑driven precision oncology company developing LP‑284, an investigational acylfulvene for aggressive B‑cell lymphomas.
Ticker impact
Lantern Pharma received a USPTO Notice of Allowance extending LP-284 patent protection to 2042, a first‑report corporate development.
Modest upside as the extended patent horizon could improve long‑term cash‑flow expectations.
Patent extensions are material for biotech valuations but the company remains early‑stage with limited near‑term revenue.
Market effects
Strengthens the IP position of AI‑driven oncology platforms, may raise confidence in similar biotech pipelines.
US biotech investors may view the filing as a positive signal for US‑listed precision‑oncology firms.
Limited; primarily relevant to investors tracking early‑stage oncology drug developers.
Counterpoint
The extended patent may not translate into commercial value without successful trial data, keeping the stock speculative.
Key entities
- companyLantern Pharma Inc.
Developer of LP‑284, AI‑driven oncology platform.
- regulatorU.S. Patent and Trademark Office
Issued the Notice of Allowance for the LP‑284 method‑of‑treatment patent.
